首页> 外国专利> EPHA4 AS THERAPEUTIC TARGET OF PRC AND PDACA

EPHA4 AS THERAPEUTIC TARGET OF PRC AND PDACA

机译:EPHA4作为中国和PDACA的治疗靶标

摘要

Objective methods for diagnosing a predisposition to developing prostate cancer (PRC) are described herein. In one embodiment, the diagnostic method involves the determining a expression level of EphA4. The present invention further provides methods of screening for therapeutic agents useful in the treatment of PRC, methods of treating PRC. The invention also features a method for inhibiting growth of a cancer cell by contacting the cell with a composition of a siRNA of EPHA4. Methods of treating cancer are also within the invention. The invention also features products, including nucleic acid sequences and vectors as well as to compositions comprising them, useful in the provided methods. The invention also provides a method for inhibiting of tumor cell, for example pancreatic cancer cell, particularly pancreatic ductal adenocarcinoma (PDACa).
机译:本文描述了诊断易患前列腺癌(PRC)的客观方法。在一个实施方案中,诊断方法涉及确定EphA4的表达水平。本发明进一步提供了筛选可用于治疗PRC的治疗剂的方法,治疗PRC的方法。本发明的特征还在于通过使癌细胞与EPHA4的siRNA的组合物接触来抑制癌细胞生长的方法。治疗癌症的方法也在本发明之内。本发明的特征还在于在提供的方法中有用的产物,包括核酸序列和载体以及包含它们的组合物。本发明还提供了抑制肿瘤细胞,例如胰腺癌细胞,特别是胰腺导管腺癌(PDACa)的方法。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号